ERBB2 and breast carcinoma: Here, patients with ER+/PGR+ (>50 %), HER2-, and TP53 wild-type breast cancers received primary NET with the addition of a CDK4/6i (Palbociclib) in case of insufficient Ki67 suppression following 2 weeks on NET monotherapy.